Introduction
============

The objective was to determine the effects of tranexamic acid (TA) on postoperative bleeding in cardiopulmonary bypass (CPB) surgery according to the 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism, the main endogenous regulator of fibrinolysis.

Methods
=======

We performed a prospective analysis on the postoperative bleeding effect of TA prophylaxis (2 g), administered before and after CPB, according to the PAI-1 polymorphism. We recorded data related to coagulation, fibrinolysis and bleeding, preoperatively, at admission (0 hours) to the ICU, and 4 hours and 24 hours postoperatively. SPSS version 15 was used.

Results
=======

We studied 50 patients (24 with TA and 26 without TA). In patients not receiving TA, significant differences were found between PAI-1 genotype groups (4G/4G; 4G/5G; 5G/5G) in chest-tube blood loss at 0 hours (*P*= 0.03), at 4 hours (*P*= 0.001) and at 24 hours (*P*= 0.009). Fresh frozen plasma was required during the ICU stay in 50% of 5G/5G, 25% of 4G/5G and none of the 4G/4G carriers (*P*= 0.021). 4G/4G patients did not show significant differences in blood loss between the TA and placebo groups. 4G/5G patients receiving TA had lower blood loss than the placebo group at 0 hours (*P*= 0.012) and at 24 hours after surgery (*P*= 0.014). In contrast, 5G/5G patients receiving TA had significantly lower blood loss compared with the placebo group at 0 hours (*P*= 0.028), at 4 hours (P = 0.008) and at 24 hours (*P*= 0.004) after surgery. Fifty-five percent of 5G/G patients in the placebo group received fresh frozen plasma during the ICU stay compared with no patients in the TA group (*P*= 0.014).

Conclusion
==========

PAI-1 5G/5G homozygotes who did not receive TA showed significantly greater postoperative bleeding than patients with other PAI-1 genotypes. The 5G/5G homozygotes who received TA showed the greatest blood-sparing benefit.
